Anti-Depressant Vortioxetine Hydrobromide 99% Purity Vortioxetine Hydrobromide Powder Vortioxetine Hydrobromide

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung-Vortioxetine Hydrobromide
• Product Name: Vortioxetine Hydrobromide
• Name: Vortioxetine Hydrobromide Powder
• Appearance: White Cryatalline Powder
• Color: White Color
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Anthelmintics
• Specific: COA
• Test Method: HPLC, UV
• Shelf Life: 2 Years
• CAS No.: 960203-27-4
• Mf: C18h22n2s.Hbr
• Heavy Metals: 5ppm
• Loss on Drying: 0.30%
• Residue Substances: 0.05%
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Xi′an Shaanxi
• Production Capacity: 5000kg/Month

Product Description

Anti-Depressant Vortioxetine Hydrobromide 99% Purity Vortioxetine Hydrobromide powder Vortioxetine Hydrobromide

Product Description

Product Details

Product Name	Vortioxetine Hydrobromide
Appearance	White Cryatalline Powder
CAS No.	960203-27-4
MF	C18H22N2S.HBr

Vortioxetine hydrobromide is considered to be a new multi-model antidepressant drug. In vitro studies have shown that it can antagonize 5-HT3, 5-HT7 and 5-HT1D receptors, activate 5-HT1A receptors, and partially activate 5Chemicalbook- HT1B receptor and inhibition of 5-HT transport. Vortioxetine (vortioxetine) is another antidepressant drug developed by Lundbeck, which aims to replace the expired patent drug citalopram.

Application&Function

Vortioxetine hydrobromide is a novel bisaryl thioalkylamine antidepressant co-developed by Takeda Japan and Lingbei, Denmark. It is used in the treatment of depression and anxiety disorders. In September 2013, it was awarded the United States. The FDA approved the listing for the treatment of major depressive disorders in adults. In October of the same year, vodisidinetin's marketing authorization application (MAA) received positive opinion from the European Medicines Agency (EMA) Human Medicine Products Committee (CHMP), 2013 In December of this year, the EMA European Commission granted wattacetin to its sales rights throughout the EU. There are four specifications for vortioxetine: 5 mg, 10 mg, 15 mg, and 20 mg.

Specification